Cargando…
Influence of proton pump inhibitor therapy on intestinal inflammation assessed by fecal calprotectin in pediatric patients
BACKGROUND: An increase in the numbers of patients with gastrointestinal symptoms has recently been observed. PURPOSE: To investigate the effects of proton pump inhibitor (PPI) therapy on intestinal inflammation in children and adolescents as confirmed by clinical manifestations and objectively asse...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Korean Pediatric Society
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6801199/ https://www.ncbi.nlm.nih.gov/pubmed/31319647 http://dx.doi.org/10.3345/kjp.2019.00115 |
_version_ | 1783460533142290432 |
---|---|
author | Kim, Su Yeong Lee, Na Mi Yun, Sin Weon Chae, Soo Ahn Lim, In Seok Choi, Eung Sang Yi, Dae Yong |
author_facet | Kim, Su Yeong Lee, Na Mi Yun, Sin Weon Chae, Soo Ahn Lim, In Seok Choi, Eung Sang Yi, Dae Yong |
author_sort | Kim, Su Yeong |
collection | PubMed |
description | BACKGROUND: An increase in the numbers of patients with gastrointestinal symptoms has recently been observed. PURPOSE: To investigate the effects of proton pump inhibitor (PPI) therapy on intestinal inflammation in children and adolescents as confirmed by clinical manifestations and objectively assessed by fecal calprotectin (FC) level measurement. METHODS: Consecutive children (aged 3–18 years) who presented with gastrointestinal symptoms and were treated with or without PPI for at least 1 month were enrolled. Patients were divided into PPI and non-PPI groups. The PPI group was further subdivided by treatment duration and type of PPI used. Stool samples were collected for FC evaluation at baseline and after treatment and clinical data and FC levels were compared between the groups. RESULTS: Fifty-one patients (15 boys, 36 girls) were enrolled in the study. The PPI group included 37 patients, while the non-PPI group included 14 patients. Clinical symptoms were not significantly different. FC levels and laboratory results, including C-reactive protein levels, white blood cell count, and absolute neutrophil count, were not statistically different before versus after PPI treatment. After treatment, FC levels decreased to 8.1 mg/kg (-575.4 to 340.3 mg/kg) in the PPI group and increased to 5.6 mg/kg (-460.0 to 186.9 mg/kg) in the non-PPI group compared to those before treatment (P=0.841). The number of patients with increased FC levels was not significantly different between the 2 groups (48.6% vs. 64.3%, P=0.363), similar to that observed in patients with an FC level > 50 mg/kg (24.3% and 7.1%, P=0.250). PPI therapy type and duration did not affect the FC levels (P=0.811 and P=0.502, respectively). CONCLUSION: Although we aimed to confirm the evidence of intestinal inflammation due to PPI use in children and adolescents through clinical symptoms and FC measurement, no significant changes were observed. |
format | Online Article Text |
id | pubmed-6801199 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Korean Pediatric Society |
record_format | MEDLINE/PubMed |
spelling | pubmed-68011992019-10-29 Influence of proton pump inhibitor therapy on intestinal inflammation assessed by fecal calprotectin in pediatric patients Kim, Su Yeong Lee, Na Mi Yun, Sin Weon Chae, Soo Ahn Lim, In Seok Choi, Eung Sang Yi, Dae Yong Korean J Pediatr Original Article BACKGROUND: An increase in the numbers of patients with gastrointestinal symptoms has recently been observed. PURPOSE: To investigate the effects of proton pump inhibitor (PPI) therapy on intestinal inflammation in children and adolescents as confirmed by clinical manifestations and objectively assessed by fecal calprotectin (FC) level measurement. METHODS: Consecutive children (aged 3–18 years) who presented with gastrointestinal symptoms and were treated with or without PPI for at least 1 month were enrolled. Patients were divided into PPI and non-PPI groups. The PPI group was further subdivided by treatment duration and type of PPI used. Stool samples were collected for FC evaluation at baseline and after treatment and clinical data and FC levels were compared between the groups. RESULTS: Fifty-one patients (15 boys, 36 girls) were enrolled in the study. The PPI group included 37 patients, while the non-PPI group included 14 patients. Clinical symptoms were not significantly different. FC levels and laboratory results, including C-reactive protein levels, white blood cell count, and absolute neutrophil count, were not statistically different before versus after PPI treatment. After treatment, FC levels decreased to 8.1 mg/kg (-575.4 to 340.3 mg/kg) in the PPI group and increased to 5.6 mg/kg (-460.0 to 186.9 mg/kg) in the non-PPI group compared to those before treatment (P=0.841). The number of patients with increased FC levels was not significantly different between the 2 groups (48.6% vs. 64.3%, P=0.363), similar to that observed in patients with an FC level > 50 mg/kg (24.3% and 7.1%, P=0.250). PPI therapy type and duration did not affect the FC levels (P=0.811 and P=0.502, respectively). CONCLUSION: Although we aimed to confirm the evidence of intestinal inflammation due to PPI use in children and adolescents through clinical symptoms and FC measurement, no significant changes were observed. Korean Pediatric Society 2019-10 2019-07-03 /pmc/articles/PMC6801199/ /pubmed/31319647 http://dx.doi.org/10.3345/kjp.2019.00115 Text en Copyright © 2019 by The Korean Pediatric Society This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Article Kim, Su Yeong Lee, Na Mi Yun, Sin Weon Chae, Soo Ahn Lim, In Seok Choi, Eung Sang Yi, Dae Yong Influence of proton pump inhibitor therapy on intestinal inflammation assessed by fecal calprotectin in pediatric patients |
title | Influence of proton pump inhibitor therapy on intestinal inflammation assessed by fecal calprotectin in pediatric patients |
title_full | Influence of proton pump inhibitor therapy on intestinal inflammation assessed by fecal calprotectin in pediatric patients |
title_fullStr | Influence of proton pump inhibitor therapy on intestinal inflammation assessed by fecal calprotectin in pediatric patients |
title_full_unstemmed | Influence of proton pump inhibitor therapy on intestinal inflammation assessed by fecal calprotectin in pediatric patients |
title_short | Influence of proton pump inhibitor therapy on intestinal inflammation assessed by fecal calprotectin in pediatric patients |
title_sort | influence of proton pump inhibitor therapy on intestinal inflammation assessed by fecal calprotectin in pediatric patients |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6801199/ https://www.ncbi.nlm.nih.gov/pubmed/31319647 http://dx.doi.org/10.3345/kjp.2019.00115 |
work_keys_str_mv | AT kimsuyeong influenceofprotonpumpinhibitortherapyonintestinalinflammationassessedbyfecalcalprotectininpediatricpatients AT leenami influenceofprotonpumpinhibitortherapyonintestinalinflammationassessedbyfecalcalprotectininpediatricpatients AT yunsinweon influenceofprotonpumpinhibitortherapyonintestinalinflammationassessedbyfecalcalprotectininpediatricpatients AT chaesooahn influenceofprotonpumpinhibitortherapyonintestinalinflammationassessedbyfecalcalprotectininpediatricpatients AT liminseok influenceofprotonpumpinhibitortherapyonintestinalinflammationassessedbyfecalcalprotectininpediatricpatients AT choieungsang influenceofprotonpumpinhibitortherapyonintestinalinflammationassessedbyfecalcalprotectininpediatricpatients AT yidaeyong influenceofprotonpumpinhibitortherapyonintestinalinflammationassessedbyfecalcalprotectininpediatricpatients |